anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
The invention discloses a pharmaceutical composition, a preparation method thereof, preparations thereof and an application thereof. The pharmaceutical composition is prepared from raw materials comprising 300-500 weight parts of wingedtooth laggera herb, 200-400 weight parts of dandelion and 200-400 weight parts of climbing groundsel herb through steps of pretreating, extracting, mixing uniformly and drying, and smashing and sieving. The preparation method comprises the steps of pretreating, mixing uniformly and drying, and smashing and sieving. The preparations refer to powder, tablets, capsules, granules, dripping pills or honeyed pills, wherein the powder, the tablets, the capsules, the granules, the dripping pills or the honeyed pills are prepared by adding pharmaceutically acceptable auxiliary materials into the pharmaceutical composition. The application refers to an application of the pharmaceutical composition in preparing anti-influenza virus drugs. The wingedtooth laggera herb is bitter, spicy and cold in nature and taste, and has effects of clearing away heat and toxic materials, diminishing swelling and relieving sore throat, and therefore the wingedtooth laggera herb is used as the principal component. The dandelion and the climbing groundsel herb are materials capable of clearing away heat and toxic materials. The dandelion also has an effect of dispelling wind and heat. The dandelion and the climbing groundsel herb are used as assistant components to assist the principle component to perform the effects of dispelling the wind and the heat, clearing away the toxic materials and relieving the sore throat. Researches show that the pharmaceutical composition has characteristics of safe and reliable curative effects, low toxic and side effects, and the like.
Differentiation syndrome, which may be life-threatening or fatal, has been observed in patients with acute promyelocytic leukemia (APL) treated with TRISENOX. In clinical trials, 16-23% of patients treated with TRISENOX for APL developed differentiation syndrome. Signs and symptoms include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy and multi-organ dysfunction. Differentiation syndrome has been observed with and without concomitant leukocytosis, and it has occurred as early as day 1 of induction to as late as the second month induction therapy. 

When TRISENOX is used in combination with tretinoin, prophylaxis with prednisone is recommended during the induction cycle [see Dosage and Administration (2.1)]. 

If differentiation syndrome is suspected, temporarily withhold TRISENOX and immediately initiate dexamethasone 10 mg intravenously every 12 hours and hemodynamic monitoring until resolution of signs and symptoms for a minimum of 3 days [see Dosage and Administration (2.3)].
After administration of a single 0.85 mg dose of terlipressin in patients with hepatorenal syndrome type 1 (HRS-1), an increase in the diastolic, systolic, and mean arterial pressure (MAP), and decrease in heart rate were evident within 5 minutes after dosing and were maintained for at least 6 hours after dosing. The maximum change in blood pressure and heart rate occurred at 1.2 to 2 hours post dose. For MAP, the estimated maximum effect was an increase of 16.2 mmHg. The estimated maximum effect for heart rate was a decrease of 10.6 beats/minute.

Cardiac Electrophysiology

The effect of terlipressin on QTc interval was evaluated in 41 patients with HRS-1. Patients received an initial dose of 1 mg terlipressin acetate every 6 hours for a period of up to 14 days. No clinically meaningful changes from baseline were detected in the trial based on the Fridericia correction method. Increases of the mean QTc interval of <10 ms were reported.
PURPOSE:To obtain a blood separation tube for sampling plasma which enables accurate measurement of the coagulation time in the diagnosis of blood agglutination troubles by arranging a thixotropic separating agent with the specific gravity intermediate between plasma and a blood cell component and an anti-blood agglutination agent provided into blood dispersably in contact therewith in a bottomed blood sampling tube. CONSTITUTION:In the inspection of an agglutination of blood, a thixotropic separating agent 15 with the specific gravity intermediate between plasma and a blood cell component is placed on the bottom of the body 11 of a blood sampling tube 10 while an anti-blood agglutination agent 12 is put on a separating agent 15 and a puncturable plug 14 made of butyl rubber or the like is applied to enable the holding the inside of the body 11 at a negative pressure. The blood sampling tube 10 uses a blood sampling needle 17 on a blood sampling holder 16 to sample blood from a patient. After the sampling of the blood, the tube is tilted to mix and a centrifugal separation is performed to separated a plasma layer 18 on the separating agent 15 and a blood cell layer 19 thereunder. After the separation, components of the layers 18 and 19 is kept from being mixed during the preservation and transportation with dispersion of the anti- agglutination agent 12 thereby facilitating the withdrawal of plasma only. Thus, plasma component can be used for inspection of agglutination to obtain a sample allowing an easy and accurate diagnosis of blood agglutination troubles.
F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
Significance and Impact: Adverse birth outcomes related to the length of gestation (preterm birth) are recognized as one of the most significant disorders in maternal-child health at a global scale. In the developed world, the preterm birth rate approximates 7%. In Malawi, the investigators have recently demonstrated that this rate more than triples to approximate 26.1%. Of the 4 million newborn deaths annually, nearly 1/3 (27%) are directly attributable to prematurity with another 36% secondary to related opportunistic infections (sepsis, pneumonia, gastrointestinal). 75% of the 4 million deaths occur within the first week of life, with the vast majority occurring in the first 48 hours. For those that do survive, there are persistent and lifelong risks due to stunted growth, chronic infection, retinopathy of prematurity, and bronchopulmonary dysplasia. The link between maternal oral health (periodontal disease in particular) and risk of preterm birth has been demonstrated across all populations (rural and urban, in both industrialized and developing regions) studied to date. However, in multiple randomized controlled trials treatment of active periodontal disease with scaling and planning during pregnancy has failed to demonstrate a significant benefit in preventing preterm birth.

Why would maternal oral health impact preterm birth? In rodents, subcutaneous inoculations with periodontal pathogens cause dose-dependent decreases in pup weights, and elicit inflammatory responses that can trigger preterm birth when present in amniotic fluid. Periodontitis (defined as a destructive inflammation of the periodontium) has a prevalence of 30% or greater in women of child bearing age. By definition, it involves microbial infiltration of the periodontium, which stimulates a chronic inflammatory response, recurrent bacteremia, and the production of cytokines and prostaglandins which trigger risk of preterm birth. It is the same production of prostaglandins which are felt to mediate the risk of preterm birth. So if the investigators know that there is biologic evidence that periodontitis is related to preterm birth, but treating active periodontitis does not reduce these morbidities, is it possible that preventing periodontitis might prevent preterm birth and low birth weight? If so, what are the least expensive efficacious preventative measures? The investigators' overarching hypothesis is that comprehensive primary preterm birth prevention, inclusive of maternal oral health with xylitol chewing gum (the intervention), will reduce the rate of periodontal disease and caries, preterm birth prevalence, and neonatal mortality.
Philadelphia chromosome-positive (Ph+) lymphoid blast crisis (BC), emanating from chronic myeloid leukemia (CML), is a fatal disease with limited treatment options. Asciminib (ABL001) is a novel selective allosteric inhibitor of the ABL kinase with high efficacy against TKI-resistant BCR::ABL1. In this study, we demonstrate significant suppression of an aggressive B-lymphoblastic disease and restoration of normal hematopoiesis in an inducible transgenic mouse model of p210-BCR::ABL1-positive CML-BC. Molecularly, asciminib treatment significantly reduced BCR::ABL1 transcripts to background levels, demonstrating its ability to suppress BCR::ABL1-induced disease. Furthermore, asciminib treatment normalized the long-term repopulating hematopoietic stem cell (LT-HSC) population in the BM, suggesting the selective targeting of malignant LT-HSCs. This was supported by secondary transplantation experiments, resulting in absence of BC in a proportion of mice. Importantly, none of the secondary transplanted mice that received further asciminib treatment developed leukemia. Sanger sequencing of the BCR::ABL1 myristoyl pocket region of both treatment-naïve and treated mice demonstrated a high mutational load. However, there was no indication of asciminib-specific mutations. These promising findings highlight the potential of asciminib as a drug that targets BC stem cells and as an alternative stand-alone or combinatorial therapy for first-line treatment of CML BC or Ph+ acute lymphoblastic leukemia.
BACKGROUND: Clostridioides difficile infection is associated with antibiotic use and manifests as diarrhea; however, emerging cases of fulminant diarrhea caused by binary toxin-producing C. difficile unrelated to prior antibiotic exposure have been reported. Although fulminant colitis caused by C. difficile has been documented, instances of intussusception remain scarce. Here, we present a case of adult intussusception with severe hypokalemia and pneumonia resulting from a community-acquired C. difficile infection in Japan.
CASE PRESENTATION: An 82-year-old male presented with dizziness, progressive weakness, and diarrhea. Initial vital signs indicated severe respiratory and circulatory distress, and laboratory findings revealed hypokalemia, pneumonia, and septic shock. Imaging confirmed intussusception of the ascending colon. Although colonoscopy suggested a potential tumor, no malignancy was found. The C. difficile rapid test result was positive, indicating community-acquired C. difficile infection. Treatment with vancomycin was initiated; however, intussusception relapsed. Surgical intervention was successful and led to clinical improvement. The patient's complex pathophysiology involved community-acquired C. difficile-induced severe diarrhea, hypokalemia, hypermetabolic alkalosis, and subsequent intussusception. Although adult intussusception is uncommon, this case was uniquely linked to binary toxin-producing C. difficile. The identified strain, SUH1, belonged to a novel sequence type (ST1105) and clade 3, suggesting a highly virulent clone. Resistome analysis aligned with phenotypic susceptibility to metronidazole and vancomycin, confirming their treatment efficacy.
CONCLUSION: This case report highlights a binary toxin-producing C. difficile that caused intussusception. The consideration of community-acquired C. difficile in the differential diagnosis of severe enteritis is necessary, even in Japan.
BACKGROUND: Minimally invasive lobectomy is the standard treatment for early stage non-small cell lung cancer (NSCLC). The aim of this study is to investigate postoperative recovery in a prospective trial of discharged patients with early stage non-small cell lung cancer undergoing robot-assisted thoracic surgery (RATS) versus uniportal video-assisted thoracic surgery (UVATS).
PATIENTS AND METHODS: This is a prospective and observational study. From 9 September 2022 to 1 July 2023, 178 patients diagnosed with NSCLC admitted to the Department of Thoracic Surgery of Shandong Provincial Hospital signed informed consent and underwent lobectomy by RATS and UVATS. The functional recovery index included MD Anderson Symptom Inventory, Christensen Fatigue Scale, EORTC QLQ-C30, and Leicester Cough Questionnaire.
RESULTS: After propensity score-matched analysis, each group included 42 cases. For the baseline characteristics of patients, operation time (p = 0.01) and length of stay (p = 0.04) were shorter in the RATS group. The number of lymph nodes resected in the RATS group was much more than in the UVATS group. According to our investigation, appetite loss, nausea, diarrhea, and cough severity after RATS were better than after UVATS. After the first week, pain severity degree of the RATS group was higher than UVATS, while there was no difference during the second and third week. The physical score of the RATS group was higher than the UVATS group (p = 0.04), according to the Leicester Cough Questionnaire.
CONCLUSION: RATS was associated with severe short-term postoperative pain but less postoperative complications.
PURPOSE:To obtain a novel anti-tumor polypeptide deficient of 11-amino acid of amino terminal of TNF, by linking a synthetic oligonucleotide with a proper promoter and introducing the obtained recombinant plasmid into E.coli. CONSTITUTION:A human TNF gene having translation-initiation codon, termination codon and a proper restriction enzyme site is designed. Said gene is divided into 3 blocks by using 17 synthetic oligonucleotides and cloned to vector pBR322. Fragment of each block (ClaI-SalI, SalI-PvuII, PvuII-HindIII) and a ClaI-HindIII fragment of a plasmid PYS31N having trp promoter are linked together and introduced into E.coli to obtain pTNF401NN. The HapII-HindIII fragment of said plasmid is linked with ClaI-HindIII fragment of pYS31N and further a synthetic oligonucleotide and the product is introduced into a host. The objective polypeptide having the amino acid sequence of formula can be produced by using said host cell.
Bone tumors refer to tumors that occur in the bone or its accessory tissues. Benign bone tumors usually reveal a good prognosis, while malignant bone tumors develop rapidly, have a poor prognosis and high mortality. Malignant bone tumors are also classified as primary tumor and secondary metastasis. Bone metastasis refers the metastasis of malignant tumors to the bone through lymph, blood or direct invasion to generate daughter tumors, which is the most common bone tumor. More than 40% of patients with malignant tumors will have bone metastasis, among which breast cancer, prostate cancer is more common. Early diagnosis of a various of bone tumors can lay the foundation for clinical implementation of effective treatment measures. The laboratory of Hank F. Kung at the University of Pennsylvania had developed a new generation of Gallium-68 labeled radiopharmaceutical P15-041 (\[68Ga\]Ga-P15-041) based on existing phosphonate-targeting molecular probes. Data from preclinical studies indicated that \[68Ga\]Ga-P15-041 shows additional advantages in rapid and easy complex formation compared to current agents. In preclinical experiments, \[68Ga\]Ga-P15-041 showed good bone resorption and rapid renal excretion in normal mice. Hong et al. prepared multiple clinical doses of \[68Ga\]Ga-P15-041 and successfully evaluated it in patients. Robert K. Doot et al. conducted dosemetric experiments on \[68Ga\]Ga-P15-041, and analyzed the radioactive distribution of the drug in normal organs and the dynamic change of the dose of the drug in the body over time. Series of research results showed that \[68Ga\]Ga-P15-041 had high uptake in the bone cortex, blood and other tissues cleared quickly. Hence, \[68Ga\]Ga-P15-041 had the potential to become a new generation of excellent phosphonate molecular probes.
Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
D-peptide compounds that specifically bind to VEGF are provided. Also provided are multivalent D-peptide compounds comprising two or more domains linked via a linking component. The multivalent (e.g., bivalent, trivalent, tetravalent, etc.) compounds may include multiple distinct domains that specifically bind to different binding sites on the target protein to provide high affinity binding to and potent activity against the VEGF target protein. Also provided are D-peptide GA and Z domains for use in the multivalent compounds, the polypeptides having a Specificity Determining Motif (SDM) for specific binding to VEGF (e.g., VEGF-a). Because the protein of interest is homodimeric (e.g., VEGF-A), the D-peptide compounds can similarly be dimeric and include dimers of multivalent (e.g., bivalent) D-peptide compounds. Also provided are methods for treating a disease or condition associated with VEGF or angiogenesis, such as age-related macular degeneration (AMD) or cancer, in a subject.
Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
PCT No. PCT/HU94/00008 Sec. 371 Date Jan. 29, 1996 Sec. 102(e) Date Jan. 29, 1996 PCT Filed Mar. 31, 1994 PCT Pub. No. WO94/22413 PCT Pub. Date Oct. 13, 1994The invention relates to pharmaceutical compositions for the treatment or prevention of lesions of gastrointestinal mucous membranes and having secretion inhibiting, cytoprotective activities. The compositions contain in a biologically effective quantity a triazole-group-substituted quinoline derivative of general formula (I) R1 stands for a 1-triazolyl-group in position 2 or 4 or a 3-triazolyl-thio or a 5-/C1-4-alkyl/-3-triazolyl-thio-group, R2 stands for a hydrogen atom in position 3 or optionally in position 2, or for a C1-4-alkyl-group, R3 stands for a hydrogen atom or for a C1-4-alkyl-group, X stands for a hydrogen or halogen-atom or for a C1-4-alkyl-group or its salts. The invention includes processes for the preparation of the above compositions, and methods for treatment of patients in need of such treatment by administering the substance or the composition. The prefered substance of formula (IV) is also subject of the invention.
Patients receive trametinib PO daily. Beginning on day 1 of course 2, patients also receive pembrolizumab IV over 30 minutes. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
With increasing volume of tumor, the dose of radiosurgery that can be safely delivered to recurrent oligo-metastases in the brain must be reduced. However, reducing the dose of radiosurgery also compromises local control. There is mounting evidence of a local control benefit to a hypofractionated approach in radiation delivery for brain metastases compared with single fraction radiosurgery. Here we propose a novel therapeutic strategy that builds on this concept whereby time between each delivered fraction will enable us to measure and adapt to response, with the objective of reducing irradiated volumes and improving outcomes. In general, the treatment of malignant tumors benefits from fractionation of the dose due to a number of radiobiological properties (redistribution, reoxygenation, repair) that distinguish, and select against, malignant lesions in the fractionation process. Hypofractionated stereotactic radiotherapy (HSRT) is a method of delivering a highly conformal dose distribution in a few treatment sessions using a relocatable stereotactic frame. HSRT may be an attractive alternative to SRS because it may 1) improve patient comfort by removing the invasive nature of SRS frames, 2) confer a radiobiologic advantage over single fraction treatment.
Dysregulated innate immunity participates in the pathomechanisms of disseminated intravascular coagulation (DIC) in trauma-induced coagulopathy. Accidental and regulated cell deaths and neutrophil extracellular traps release damage-associated molecular patterns (DAMPs), such as histones, nuclear and mitochondrial DNA, and high-mobility group box 1, into circulation immediately after trauma. DAMP-induced inflammation activation releases tissue factor-bearing procoagulant extracellular vesicles through gasdermin D-mediated pore formation and plasma membrane rupture by regulated cell death. DAMPs also evoke systemic inflammation, platelet, coagulation activation, and impaired fibrinolysis associated with endothelial injury, leading to the dysfunction of anticoagulation systems, which are the main pathophysiological mechanisms of DIC. All these processes induce systemic thrombin generation in vivo, not restricted to the injury sites immediately after trauma. Thrombin generation at the site of injury stops bleeding and maintains homeostasis. However, DIC associated with endothelial injury generates massive thrombin, enhancing protease-activated, receptor-mediated bidirectional interplays between inflammation and coagulation, aggravating the diverse actions of thrombin and disturbing homeostasis. Insufficiently regulated thrombin causes disseminated microvascular thrombosis, resulting in tissue hypoxia due to reduced oxygen delivery, and mitochondrial dysfunction due to DAMPs causes tissue dysoxia. In addition, DAMP-induced calcium influx and overload, as well as neutrophil activation, play a role in endothelial cell injury. Tissue hypoxia and cytotoxicity result in multiple organ dysfunction in DIC after trauma. Controls against dysregulated innate immunity evoking systemic inflammation, thrombin generation, and cytotoxicity are key issues in improving the prognosis of DIC in trauma-induced coagulopathy.
The present invention provides systems, instruments and methods for determining genetic or molecular aberrations in a biological sample from an organism. Biological samples comprising free DNA fragments are analyzed to identify imbalances that exist in chromosomal regions, e.g., due to chromosomal deletions and/or amplifications in tumors. Multiple loci were used for analysis of individual chromosomal regions. Such imbalances can then be used to diagnose (screen) cancer and prognosis of cancer patients, or to detect or monitor changes in a pre-malignant health state of a patient. The severity of the genomic imbalance and the number of regions of imbalance can be used to provide diagnosis, screening, prognosis, and monitoring. Systematic analysis of non-overlapping chromosome segments can provide a universal cancer screening tool. In addition, the patient can be tested at different time points to track the severity of one or more chromosomal regions and each of a number of chromosomal regions, as well as the number of chromosomal regions exhibiting chromosomal aberrations, to enable screening, prognostic diagnosis of cancer, and monitoring of lesion progression (e.g., after treatment).